<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36059">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637141</url>
  </required_header>
  <id_info>
    <org_study_id>CELIM-NRCD-001</org_study_id>
    <secondary_id>2015-003647-19</secondary_id>
    <nct_id>NCT02637141</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celimmune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol CELIM-NRCD-001 is designed to be a Phase 2a, randomized, double-blind,
      placebo-controlled, parallel-group study to evaluate the efficacy and safety of AMG 714 for
      the attenuation of the effects of gluten exposure in adult patients with celiac disease
      during a gluten challenge.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attenuation of gluten-induced small intestinal mucosal injury as assessed by the change from baseline to Week 12 in Vh:Cd ratio</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The Vh:Cd is the morphometric measure of the length of the small intestinal villi with respect to the depth of the crypts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Attenuation of gluten-induced small intestinal mucosal inflammation at Week 12 compared to baseline, as measured by the enumeration of intraepithelial lymphocytes (IELs) in histological sections</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Small bowel biopsies will be processed and stained with hematoxylin-eosin stains, and the IELs counted per 100 epithelial cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attenuation of gluten-induced serum antibodies at Week 12 compared to baseline (anti-deamidated gliadin peptides, DGP) and autoantibodies (anti-transglutaminase, ATG)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>DGP and ATG antibodies will be measured in serum by ELISA technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attenuation at Week 12 compared to baseline, of gluten-induced clinical symptoms as measured by the Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The GSRS questionnaire will be filled at every visit (approximately monthly)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and Tolerability of AMG 714 as assessed by the proportion of subjects with drug related adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse events and serious adverse events will be captured on an on-going basis from screening to study end.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>AMG 714 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 714 150 mg SC every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 714 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 714 300 mg SC every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC every two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 714</intervention_name>
    <description>A fully human anti-IL-15 monoclonal antibody</description>
    <arm_group_label>AMG 714 150 mg</arm_group_label>
    <arm_group_label>AMG 714 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of celiac disease by intestinal biopsy at least 12 months prior to
             screening

          -  On a gluten-free diet for at least 12 months

          -  Negative celiac serology

          -  Avoidance of pregnancy

        Exclusion Criteria:

          -  Severe complications of celiac disease, such as refractory celiac disease

          -  Celiac symptoms

          -  Other concomitant autoimmune disease

          -  Chronic, active GI disease

          -  Infections, concomitant diseases

          -  Prohibited medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markku Maki, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tampere University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ODL</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRST</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.celimmune.com</url>
  </link>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 11, 2016</lastchanged_date>
  <firstreceived_date>November 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>celiac</keyword>
  <keyword>gluten</keyword>
  <keyword>IL-15</keyword>
  <keyword>AMG 714</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publication in peer-reviewed journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
